Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Get Thin MD vs Midi Health

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.9

Get Thin MD

Best for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available
★★★★4

Starting at $169/mo

CompoundedSemaglutideTirzepatideBrand
Visit Get Thin MD
7.0

Midi Health

Best for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss product
★★★3.5

Starting at $128/mo

Menopause SpecialtyCompounded SemaglutideAll 50 StatesCommercial Insurance Accepted
Visit Midi Health

Side-by-Side Comparison

FeatureGet Thin MDMidi Health
Overall Score7.9/107.0/10
Starting Price$169/mo$128/mo
Editorial Rating4 ★ /53.5 ★ /5
Features7 features4 features
States Available00
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Get Thin MD

Pros

  • 3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
  • Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
  • Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
  • Nationwide availability with async evaluation — no in-person visit required
  • Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
  • Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."

Cons

  • Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
  • Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
  • State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
  • Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
  • Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix

Midi Health

Pros

  • Nationwide availability in all 50 states (verified on the public homepage)
  • Accepts commercial insurance — differentiator vs most cash-pay-only GLP-1 telehealth
  • Menopause + metabolic health specialty framing — useful for women in the demographic where GLP-1 efficacy and weight regulation overlap most
  • Compounded semaglutide pricing starts at $127.90/mo for uninsured patients per the public pricing/insurance page

Cons

  • Does NOT accept Medicare, Medicaid, or Medi-Cal — eliminates roughly 40% of the insured US adult population
  • GLP-1 prescribing is clinician-discretionary inside a broader menopause care plan, NOT a guaranteed offering at intake — readers signing up purely for GLP-1 access may not get it
  • Menopause-focused — not the right fit for men or younger women whose primary need is weight loss

Our Verdict

Winner: Get Thin MDScore: 7.9/10

Get Thin MD edges out Midi Health with a higher overall score of 7.9/10 and is particularly strong for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available. Midi Health remains a solid alternative, especially if you're looking for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss product.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.